City Of Hope
Trial of CAR-T for prostate cancer takes steps toward ‘potentially curative’ therapy
Chimeric antigen receptor T-cell therapy exhibited activity with minimal adverse effects for men with advanced prostate cancer, findings of a first-in-human trial showed.
Conference to take ‘full-circle’ approach to evidence-based integrative oncology
City of Hope will host Society for Integrative Oncology’s 21st International Conference from Oct. 25-27.
City of Hope Orange County appoints executive medical director of colorectal surgery
Alessio Pigazzi, MD, PhD, has been appointed executive medical director of colorectal surgery at City of Hope Orange County.
Altering gut microbiome may benefit patients with metastatic kidney cancer
Combining gut microbiome manipulation with immunotherapy and tyrosine kinase inhibitor therapy conveyed clinical benefit for patients with metastatic renal cell carcinoma, results of a randomized phase 1 trial showed.
Younger generations at increased risk for several cancer types
Incidence rates for 17 different cancer types increased for successively younger generations in the United States during the past century.
Early findings suggest CAR-T for solid tumors may advance beyond ‘very nascent stage’
It’s only the beginning.
MD Anderson again ranked best cancer hospital in U.S.
The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.
Lung cancer dominates ASCO social media conversation among health care professionals
Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.
Positive results in lung cancer show benefits of subcutaneous bispecifics
CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.
New approach ‘redefining what is a suitable donor’ for stem cell transplant
CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.